Carl Zeiss Meditec ((DE:AFX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Carl Zeiss Meditec is conducting a clinical study titled ‘EPIC: Evaluation of the Postoperative Cataract Surgery Outcomes in Patients With Prior Corneal Laser Vision Correction Implanted With the CT LUCIA Intraocular Lens.’ The study aims to assess the visual and refractive outcomes in patients who have undergone myopic corneal laser vision correction and are now receiving the CT LUCIA 621P intraocular lens during cataract surgery. This research is significant as it seeks to improve understanding of postoperative results in this specific patient group.
Intervention/Treatment: The study tests the CT LUCIA 621P intraocular lens, a device designed to enhance visual quality and refractive stability in patients undergoing cataract surgery. This lens is implanted bilaterally in patients with a history of myopic corneal laser vision correction.
Study Design: This is a prospective, observational cohort study. It does not involve random allocation or masking, focusing instead on observing outcomes in a real-world setting. The primary purpose is to evaluate postoperative visual and refractive outcomes.
Study Timeline: The study began in July 2025, with primary completion expected shortly after. The most recent update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
Market Implications: The study’s outcomes could significantly impact Carl Zeiss Meditec’s stock performance, as positive results may enhance the marketability of the CT LUCIA 621P lens. Investors should monitor this development, especially in the context of competitors in the ophthalmic device industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.